INFILBRAY
Live / Applied — Second extension granted (statement of use) (as of 19 Dec 2025)
What this means for you
Not registered yet, but its 18 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98363007
- Mark type
- Stylized text
- Filed
- 18 Jan 2024
- Published for opposition
- 17 Dec 2024
- Attorney of record
- Alexandra Kochian
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system; pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases; pharmaceutical preparations for the treatment of rare diseases, namely, lysosomal storage disorders and autosomal dominant polycystic kidney disease; pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 19 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Dec 2025 — SOU EXTENSION 2 GRANTED
- 19 Dec 2025 — SOU EXTENSION 2 FILED
- 19 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Jun 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 26 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 26 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 26 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 30 Jun 2025 — SOU EXTENSION 1 GRANTED
- 30 Jun 2025 — SOU EXTENSION 1 FILED
- 30 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Dec 2024 — PUBLISHED FOR OPPOSITION